RECRUITING

Biomarkers Related to Bone in Pediatric Gaucher Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Aims of the observational study is to establish novel blood-based biomarkers for grading bone disease in pediatric patients with Gaucher disease (GD). Patients with clinically confirmed GD: deficient GCase enzyme activity and corresponding genetic analysis will be eligible for enrollment. Levels of Lyso-Gb1, chitotriosidase, and CCL18 will be established for future bone biomarkers correlation analysis. Skeletal involvement will be assessed using standard clinical diagnostic tools, such as skeletal radiology and/or (DEXA). The comparator group will include age-matched healthy controls. Clinically confirmed patients with GD will be stratified based on their disease severity (Gaucher disease type 1 and Gaucher disease type 3) and bone pathology findings. In addition, given that growth is a dynamic process during the pediatric age group, results will be ascertained with respect to phases of growth, i.e., early childhood, late childhood, adolescent, and young adult age groups. At the conclusion of the study, investigatirs expect to establish specific biomarkers of bone development and pathology in pediatric GD patients.

Official Title

Pilot Study to Assess Immune Biomarkers and Growth Factors Related to Bone Pathology in Pediatric Patients With Gaucher Disease

Quick Facts

Study Start:2023-11-25
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06116071

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:5 Years to 21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. The parent or legal guardian and the participant who is eligible to provide assent are able and willing to provide informed consent and assent when applicable.
  2. 2. The participant is 5-21 years of age at the initial visit.
  3. 3. The participant has a confirmed diagnosis of GD type 1 or type 3 (biochemically and/or genetically).
  4. 4. In the investigator's opinion, the subject is capable of understanding and complying with protocol requirements.
  5. 5. The subject or, when applicable, the subject's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  1. 1. Any subject who does not meet any of the following criteria will not qualify for the study.
  2. 2. Any current active chronic infection such as HIV, Hepatitis B or C.
  3. 3. Pregnancy or breastfeeding for females.

Contacts and Locations

Study Contact

Margarita Ivanova, PhD
CONTACT
5714592367
mivanova@ldrtc.org
Loren Noll, MS
CONTACT
5714592367
lnoll@ldrtc.org

Principal Investigator

Ozlem Goker-Alpan, MD
PRINCIPAL_INVESTIGATOR
Lysosomal and Rare Disorders Research and Treatment Center

Study Locations (Sites)

Lysosomal and Rare disorder research and treatment center
Fairfax, Virginia, 22030
United States

Collaborators and Investigators

Sponsor: Lysosomal and Rare Disorders Research and Treatment Center, Inc.

  • Ozlem Goker-Alpan, MD, PRINCIPAL_INVESTIGATOR, Lysosomal and Rare Disorders Research and Treatment Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-25
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2023-11-25
Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Gaucher Disease
  • Bone Diseases